Form 4: Assertio Holdings Acquired by Zydus in $23.50 Cash Deal

CEO Mark L. Reisenauer reports the disposal of all equity holdings following the completion of Assertio Holdings' acquisition by Zydus Worldwide DMCC.

Summary

• Assertio Holdings, Inc. (ASRT) completed its merger with Zydus Worldwide DMCC on June 16, 2026.
• All outstanding shares of common stock were cancelled and converted into the right to receive $23.50 per share in cash.
• CEO Mark L. Reisenauer disposed of his remaining 3,583 shares of common stock as part of the merger.
• All outstanding restricted stock units (RSUs) and stock options were cancelled and converted into cash payments based on the $23.50 offer price, subject to applicable withholding taxes.
• Stock options with exercise prices equal to or greater than the offer price were cancelled without payment.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing confirming the successful completion of a previously announced merger.

Positives

• Shareholders received a cash exit at $23.50 per share.
• Unvested restricted stock units were accelerated and vested immediately prior to the merger effective time.
• In-the-money stock options were converted into cash payments.

Negatives

• Out-of-the-money stock options were cancelled without any cash payment.
• The company has ceased to be an independent publicly traded entity.

Risks

• The company is now a wholly owned subsidiary of Zydus, eliminating independent shareholder control.

Future Outlook

The company has been acquired and is now a wholly owned subsidiary of Zydus Worldwide DMCC; no further independent public guidance is provided.

Management Comments

• The filing confirms the completion of the merger and the conversion of all equity interests into cash.

Industry Context

StockSavvy.ai notes that this acquisition represents a consolidation trend in the pharmaceutical sector, where larger entities like Zydus are absorbing smaller, specialized firms to expand their product portfolios.

Comparison to Industry Standards

• The $23.50 cash-out price represents the final valuation for public shareholders.
• The treatment of unvested RSUs and in-the-money options is consistent with standard change-of-control provisions in pharmaceutical M&A.

Legal Proceedings

• The transaction was executed pursuant to a Merger Agreement dated May 13, 2026.

Stakeholder Impact

• Shareholders have been cashed out at the agreed offer price.
• Employees and management are now part of the Zydus organization.

Next Steps

• Delisting of Assertio Holdings common stock from public exchanges.

Key Dates

Keywords

Assertio Holdings, ASRT, Merger, Acquisition, Zydus, Form 4, Insider Transaction